Alert: Negative Investment/Fundamental Signals (4/3/24)-Amicus Therapeutics Inc (NASDAQ: FOLD)


Amicus Therapeutics Inc (NASDAQ: FOLD) has recently experienced notable negative changes in fundamentals: the stock’s power rating fell below 50, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.

Amicus Therapeutics Inc (NASDAQ: FOLD) has recently experienced meaningful negative changes in investment behavior: negative upside/downside volume developed.

In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.


Current PriceTarget Research Rating

With future capital returns forecasted to be above the cost of capital, FOLD is expected to continue to be a major Value Builder.

Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Amicus Therapeutics has a slightly negative Power Rating of 32 and a very low Appreciation Score of 11, resulting in the Lowest Value Trend Rating.

Recent Price Action

Amicus Therapeutics Inc (NASDAQ: FOLD) stock closed at $11.37 on 4/3/24 after being unchanged was unchanged. Moreover, trading volume in this flat performance was above average at 140% of normal. The stock has declined -1.5% during the last week and has performed in line with the market over the last nine months.

Be the first to comment

Leave a Reply

Your email address will not be published.